IRIDEX Corporation

IRIDEX Corp is an ophthalmic medical technology company that develops and commercializes laser-based systems and related therapies for sight-threatening eye diseases. Its core focus is on glaucoma and retinal disorders, using proprietary MicroPulse and Endpoint Management technologies to deliver tissue-sparing treatment modes in select laser consoles.

−3,9 %

36,5 %

−8,4 %

+8,2 %

1.91

1.32

— IRIDEX Corporation
%
Glaucoma systems24% Laser-based products and treatment modes used to manage glaucoma, including Cyclo G6.
Retina systems59% Products and procedures used to treat retinal diseases and related eye conditions.
Other products16% Additional ophthalmic devices, accessories, and related product sales outside the core glaucoma and retina groups.
Services and support1% Service revenue and support activities tied to installed systems and customer use.

IRIDEX sells primarily to eye-care providers that need capital equipment and treatment solutions for glaucoma and...

  • Hospitals and surgical centersprimary

    Buy ophthalmic laser systems for glaucoma and retina procedures, often as capital equipment tied to procedure volume.

  • Physician officesprimary

    Purchase systems for in-office treatment of sight-threatening eye conditions and to expand procedure offerings.

  • International distributorssecondary

    Buy or place products for resale outside the U.S., extending market reach and local service coverage.

  • Clinicians and treatment centerssecondary

    Adopt proprietary treatment modes because they can deliver low-energy, tissue-sparing therapy.

IRIDEX is headquartered in the United States, but it also sells internationally through distributors and direct end...

  • •United States is the core market for capital equipment and procedures
  • •International distributors expand reach into non-U.S. ophthalmology markets
  • •German office supports direct euro-denominated end-user sales
  • •Foreign exchange can affect pricing and reported profitability
  • •International mix can pressure gross margin when sales shift abroad

IRIDEX is focused on commercializing its proprietary laser therapy technologies and expanding adoption in glaucoma and...

01
Increase adoption of proprietary treatment modesmedium-term

MicroPulse and Endpoint Management differentiate the company’s systems and support clinical adoption.

02
Strengthen retina and glaucoma commercial executionshort-term

Revenue growth depends on converting clinical demand into capital equipment purchases and procedure use.

03
Maintain liquidity and funding flexibilityshort-term

The company expects current cash to cover 12 months, but future growth may require additional capital.

04
Improve manufacturing and cost structuremedium-term

Gross margin is sensitive to manufacturing costs, product mix, and international mix.

IRIDEX is exposed to cyclical capital equipment demand, since hospitals and physician offices can delay purchases when...

high

Delayed capital equipment purchasing by customers

Hospitals, surgical centers, and physician offices may defer buying laser systems during recessionary or uncertain periods.

Scope
Revenue timing and order conversion
Materiality
high
high

Tariffs and trade-war related cost inflation

Imported components and cross-border sales can be affected by tariff changes and retaliatory actions.

Scope
Manufacturing costs and international demand
Materiality
high
medium

Foreign exchange pressure on international sales

A stronger U.S. dollar can make products more expensive abroad and reduce demand or profitability in local markets.

Scope
International distributor and euro-denominated direct sales
Materiality
medium
medium

Margin compression from product and geographic mix

Capital system sales and international mix can lower gross margin when manufacturing costs rise.

Scope
Gross profit and operating leverage
Materiality
high
medium

Financing and dilution risk

The company may need additional capital for R&D, sales expansion, or manufacturing investment.

Scope
Liquidity and shareholder dilution
Materiality
medium
Revenue recognition by product and channel
Affects quarterly revenue timing and comparability
Inventory, warranty, and manufacturing cost estimates
Directly affects gross margin
Foreign currency effects
Can change reported revenue and profitability
Convertible preferred shares and convertible debt
Affects capital structure and per-share results

IRIDEX CORP

IRIX · Electromedical & Electrotherapeutic Apparatus

IRADIMED CORP

IRMD · Surgical & Medical Instruments & Apparatus

IR-Med, Inc.

Electromedical & Electrotherapeutic Apparatus

Nurix Therapeutics, Inc.

NRIX · Pharmaceutical Preparations

IMMUNIC, INC.

IMUX · Pharmaceutical Preparations

ARDELYX, INC.

ARDX · Pharmaceutical Preparations

: 28.4.2026